Eli Lilly

News

Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main rival Wegovy from Novo Nordisk.

News

Eli Lilly has added another candidate to a growing pipeline of therapies for ALS, tapping Alchemab for an antibody sourced from 'resilient' patients.

News

Shares in Eli Lilly have weakened after pharmacy benefit manager CVS Health said it would no longer cover its weight-loss therapy Zepbound.

News

Novo Nordisk has enlisted the aid of major telehealth companies as it tries to dominate the self-pay market for obesity drugs in the US.

News

Shares in Eli Lilly rose sharply in pre-market trading today after it reported phase 3 results for oral diabetes and weight-loss drug orforglipron.

News

A proposal by the Biden administration to cover weight-loss medicines for obesity under Medicare has been axed by the White House.